Immunome Inc.·4

Mar 12, 6:05 AM ET

BIENAIME JEAN JACQUES 4

4 · Immunome Inc. · Filed Mar 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Immunome (IMNM) Director Bienaime Buys 2,000 Shares

What Happened
Bienaime Jean Jacques (Director) purchased a total of 2,000 shares of Immunome Inc. in two open‑market transactions. On 2026-03-10 he bought 1,000 shares at $22.12 each ($22,120) and on 2026-03-11 he bought 1,000 shares at $21.55 each ($21,550), for a combined outlay of $43,670. These were purchases (transaction code P), which are generally treated by investors as potentially more informative than routine sales.

Key Details

  • Transactions:
    • 2026-03-10 — 1,000 shares @ $22.12 = $22,120 (open‑market purchase)
    • 2026-03-11 — 1,000 shares @ $21.55 = $21,550 (open‑market purchase)
  • Total acquired: 2,000 shares for $43,670.
  • Shares owned after the transactions: Not disclosed in the provided Form 4 excerpt.
  • Footnotes/Plans: No 10b5‑1 plan, tax withholding, or other footnotes were disclosed in the details provided.
  • Filing timeliness: Report filed 2026-03-12 for trades on 03-10 and 03-11 — appears to have been filed within the usual Form 4 reporting window.

Context
These were straightforward open‑market purchases by a board director (not a derivative exercise or gift). Purchases by insiders can attract attention from retail investors because they signal the insider was willing to deploy personal capital, but filings do not state the insider’s motive.

Insider Transaction Report

Form 4
Period: 2026-03-10
Transactions
  • Purchase

    Common Stock

    2026-03-10$22.12/sh+1,000$22,12037,415 total
  • Purchase

    Common Stock

    2026-03-11$21.55/sh+1,000$21,55038,415 total
Signature
/s/ Sandra Stoneman, Attorney-in-Fact|2026-03-12

Documents

1 file
  • 4
    form4-03122026_060301.xmlPrimary